Last reviewed · How we verify
NCT03542123: COAST-HF FX
Cardiac Output Autonomic Stimulation Therapy for Heart Failure - Hemodynamic Effects
NA trial testing NeuroTronik CANS Therapy® System in Heart Failure Acute in 30 participants. Status unknown.
1 June 2019
Quick facts
| Lead sponsor | NeuroTronik Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 30 |
| Start date | 5 June 2018 |
| Primary completion | 1 June 2019 |
| Estimated completion | 1 July 2019 |
| Sites | 1 location across Paraguay |
Drugs / interventions tested
- NeuroTronik CANS Therapy® System
Conditions studied
- Heart Failure Acute — all drugs for Heart Failure Acute →
- Heart Failure — all drugs for Heart Failure →
Sponsor
NeuroTronik Inc.
Who can join
Adults 21 to 75, any sex, with Heart Failure Acute or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A single-arm study to observe NeuroTronik Cardiac Autonomic Nerve Stimulation (CANS) Therapy System hemodynamic and other physiologic effects.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI<sub>2</sub>P<sub>2</sub>S classification.
de Oliveira Cardoso C, Elgalad A, Li K, Perin EC. · · 2022 · cited 6× · PMID 36211544 · DOI 10.3389/fcvm.2022.962839 -
Advances and controversies in acute decompensated heart failure treatment: beta-blocker roles, emerging devices, and future directions.
Milhem F, Almur O, Hajjeh O, Bdair M, et al · · 2025 · PMID 40901193 · DOI 10.1097/ms9.0000000000003592
Verify or expand the search:
- PubMed search for NCT03542123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure Acute
Currently open trials in the same condition.
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07159269 — Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers · NA · recruiting
- NCT06819618 — Prediction of Heart-Failure with Machine Learning · recruiting
- NCT06414928 — Prognostic Model Heart Failure · recruiting
- NCT05447598 — Remote Monitoring After Heart Failure · NA · active not recruiting
Other NeuroTronik Inc. trials
Trials by the same sponsor.
- NCT03169803 — Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF) · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03542123 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NeuroTronik Inc.
- Last refreshed: 23 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03542123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing